Sustained clinically meaningful efficacy and consistent safety in patients with agitation associated with dementia due to Alzheimer’s disease treated with brexpiprazole: a 24‐week <i>post hoc</i> analysis

Brexpiprazole 2 or 3 mg/day was associated with sustained clinically meaningful efficacy over 24 weeks in patients with agitation associated with dementia due to Alzheimer's disease. Longer-term treatment with brexpiprazole over the 24-week period was not associated with additional safety signals.